Celgene Scores First China Approval In Revlimid
This article was originally published in PharmAsia News
Executive Summary
One of the leading U.S. biotechs is ready to enter China after receiving its first regulatory approval.
One of the leading U.S. biotechs is ready to enter China after receiving its first regulatory approval. Celgene Inc. announced that China’s State FDA has approved its top product Revlimid (lenalidomide) as a second-line therapy for relapsed or refractory multiple melanoma in combination with dexamethason. Celgene expects to launch the product in the second quarter. (Click here for more – a subscription may be required)
“China Approves Celgene's Revlimid for Multiple Melanoma; FDA Sets Priority Review” – Wall Street Journal (2/11/2013)